---
title: "12 Health Care Stocks Moving In Monday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293213264.md"
description: "In Monday's pre-market session, several healthcare stocks showed significant movement. Gainers included Advanced Biomed (+24.1%), Barinthus Biotherapeutics (+10.17%), HCW Biologics (+10.0%), Camp4 Therapeutics (+9.97%), Atara Biotherapeutics (+7.27%), and Genenta Science (+7.09%). Conversely, losers featured BioVie (-15.6%), GlucoTrack (-13.4%), Bluejay Diagnostics (-11.04%), Valion Bio (-10.94%), Elutia (-9.48%), and GRI Bio (-9.34%)."
datetime: "2026-07-20T12:05:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293213264.md)
  - [en](https://longbridge.com/en/news/293213264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293213264.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Monday's Pre-Market Session

### Gainers

-   **Advanced Biomed** (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million.
-   **Barinthus Biotherapeutics** (NASDAQ:BRNS) shares rose 10.17% to $0.61. The market value of their outstanding shares is at $22.6 million.
-   **HCW Biologics** (NASDAQ:HCWB) shares rose 10.0% to $4.4. The company's market cap stands at $6.3 million.
-   **Camp4 Therapeutics** (NASDAQ:CAMP) stock rose 9.97% to $4.08. The market value of their outstanding shares is at $192.6 million.
-   **Atara Biotherapeutics** (NASDAQ:ATRA) shares rose 7.27% to $9.0. The company's market cap stands at $75.5 million.
-   **Genenta Science** (NASDAQ:GNTA) stock increased by 7.09% to $1.66. The market value of their outstanding shares is at $36.3 million.

### Losers

-   **BioVie** (NASDAQ:BIVI) shares decreased by 15.6% to $1.52 during Monday's pre-market session. The market value of their outstanding shares is at $13.5 million.
-   **GlucoTrack** (NASDAQ:GCTK) shares declined by 13.4% to $0.43. The company's market cap stands at $3.2 million.
-   **Bluejay Diagnostics** (NASDAQ:BJDX) stock decreased by 11.04% to $1.29. The company's market cap stands at $1.5 million.
-   **Valion Bio** (NASDAQ:VBIO) shares decreased by 10.94% to $0.45. The market value of their outstanding shares is at $1.6 million.
-   **Elutia** (NASDAQ:ELUT) shares fell 9.48% to $0.86. The market value of their outstanding shares is at $41.9 million.
-   **GRI Bio** (NASDAQ:GRI) shares fell 9.34% to $1.36. The company's market cap stands at $2.6 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [BRNS.US](https://longbridge.com/en/quote/BRNS.US.md)
- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)
- [ATRA.US](https://longbridge.com/en/quote/ATRA.US.md)
- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)
- [ELUT.US](https://longbridge.com/en/quote/ELUT.US.md)
- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)
- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)
- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)
- [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md)
- [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md)
- [GRI.US](https://longbridge.com/en/quote/GRI.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [GlucoTrack Amends Warrant Terms Pending Shareholder Approval](https://longbridge.com/en/news/298966633.md)
- [GlucoTrack Settles Disputed Debt with Convertible Note](https://longbridge.com/en/news/298511271.md)
- [BIVI: Bezisterim showed significant symptom improvement in Long COVID patients with high baseline burden](https://longbridge.com/en/news/299062593.md)
- [BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid | BIVI Stock News](https://longbridge.com/en/news/298957711.md)
- [GlucoTrack amends private placement warrants, ties exercise to shareholder approval under Nasdaq rules](https://longbridge.com/en/news/298958562.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**